Search
CONGRESS 2023 - Clinical Liaison Role in Wales – an update on the journey so far
27/09/2023
Clinical Liaison Role in Wales – an update on the journey so far
CONGRESS 2023 - Coagulation for Blood Bankers: Help! I’ve lost the clot….
27/09/2023
Coagulation tests can be confusing, but correct interpretation is crucial to guide transfusion of blood products and haemostatic agents. Advantages and limitations of these tests will be discussed, using a variety of examples to demonstrate potential pitfalls.
Learning outcomes:
Understand appropriate use and limitations of coagulation tests
Interpretation of abnormal results
How results can guide transfusion of blood products
Recognise alternatives to blood products for haemostatic support
Learning outcomes:
Understand appropriate use and limitations of coagulation tests
Interpretation of abnormal results
How results can guide transfusion of blood products
Recognise alternatives to blood products for haemostatic support
CONGRESS 2023 - Evolution of infectious disease Point-of-Care Testing (POCT) across Wales - National POCT Lead perspective
27/09/2023
Learn how infectious disease POCT services have evolved across Wales. Discover how Louise's role as a Biomedical Scientist has evolved to National infectious disease POCT lead. Discover how POCT projects are contributing towards the World Health Organisations Hepatitis C elimination targets and how we foresee future POCT services expanding.
CONGRESS 2023 - FMT/NICE guidance
27/09/2023
Clostridioides difficile is responsible for the eponymous C. difficile infection (CDI). Faecal microbiota transplant (FMT), a NICE recommended treatment for recurrent CDI, is effective but logistic and safety concerns remain.
With the advent of non-donor derived products, the presentation will outline the principles and evidence related to correcting gut dysbiosis and explore whether there is a need for current or expanded FMT services in the future.
With the advent of non-donor derived products, the presentation will outline the principles and evidence related to correcting gut dysbiosis and explore whether there is a need for current or expanded FMT services in the future.
CONGRESS 2023 - Gender: lets talk about sex... and the implications for pathology
27/09/2023
Blood Transfusion follows binary guidelines designed to protect against the formation of allo red cell antibodies capable of causing Haemolytic Disease of the Foetus and Newborn. For the first time, in 2021, the England and Wales Census included a gender identity question, ‘Is the gender you identify with the same as your sex registered at birth?’. 0.5% of respondents answered ‘No’ (262 000 people) of which 48 000 identified as a trans man, 30 000 as non-binary and 18 000 as another gender identity. Thus, there is a small, but significant, population of Transgender and Gender Diverse (TGD) individuals in society.
What are the implications for Blood Transfusion? There are several scenarios:
The lab could receive a sample labelled male and issue blood components which fail to meet the requirements of Kell negative and, if applicable, CDE negative red cells to someone with childbearing potential.
The lab could receive an antenatal sample labelled male and the LIMS does not allow staff to perform all the same testing and product issuing as it would for a female.
Some TGD individuals who have transitioned may get a new NHS number. Lab staff may be unaware and lab records are not merged which means all future transfusion requests are relying solely on antibody screening results with no historical transfusion information.
The clinical consequences of these errors are missed incompatibilities, special requirements not met (SRNM) errors and immediate or delayed transfusion reactions with a potential for major morbidity or mortality.?All the circumstances described above illustrate that provision of healthcare is not uniform?for?all patients in the UK and could be described as indirect discrimination - a policy or practice that is identical for all people but has an unfair or disproportionate effect on a people with a protected characteristic.
What are the implications for Blood Transfusion? There are several scenarios:
The lab could receive a sample labelled male and issue blood components which fail to meet the requirements of Kell negative and, if applicable, CDE negative red cells to someone with childbearing potential.
The lab could receive an antenatal sample labelled male and the LIMS does not allow staff to perform all the same testing and product issuing as it would for a female.
Some TGD individuals who have transitioned may get a new NHS number. Lab staff may be unaware and lab records are not merged which means all future transfusion requests are relying solely on antibody screening results with no historical transfusion information.
The clinical consequences of these errors are missed incompatibilities, special requirements not met (SRNM) errors and immediate or delayed transfusion reactions with a potential for major morbidity or mortality.?All the circumstances described above illustrate that provision of healthcare is not uniform?for?all patients in the UK and could be described as indirect discrimination - a policy or practice that is identical for all people but has an unfair or disproportionate effect on a people with a protected characteristic.
CONGRESS 2023 - Generation X,Y,Z: Ageism in the workplace and its impact on service delivery
27/09/2023
Generation X,Y,Z: Ageism in the workplace and its impact on service delivery